Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

被引：24

作者：

Castellanos, Emily H. ^{[1
]}

Horn, Leora ^{[1
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Dept Hematol & Oncol, Nashville, TN 37232 USA

来源：

ONCOLOGIST | 2016年 / 21卷 / 06期

关键词：

Non-small cell lung cancer; Anaplastic lymphoma kinase; Oligoprogression; Targeted therapy; ACQUIRED-RESISTANCE; DISEASE FLARE; ALK; CRIZOTINIB; INHIBITOR; DISCONTINUATION; CHEMOTHERAPY; ERLOTINIB; CRITERIA; MUTATIONS;

D O I：

10.1634/theoncologist.2015-0396

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The advent of crizotinib, the first small molecule inhibitor against anaplastic lymphoma kinase (ALK), has led to impressive advances in the care of patients with advanced ALK-rearranged non-small cell lung cancer. The development of second-generation ALK inhibitors, starting with the recent U.S. Food and Drug Administration approval of ceritinib, promises to expand the therapeutic landscape for this cohort of patients. With increasing use of molecularly targeted therapy options, it has been observed that disease progression in patients receiving targeted agents has a heterogeneous biology, manifesting as either oligoprogressive or widely progressive disease, which may require development of innovative treatment strategies. This review discusses the first-and second-generation ALK inhibitors approved or in clinical development, as well as the novel challenges and approaches to disease progression in patients on targeted agents.

引用

页码：755 / 761

页数：7

共 53 条

[21] The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non-Small Cell Lung Cancer Growth [J].

Garon, Edward B. ;

Finn, Richard S. ;

Hamidi, Habib ;

Dering, Judy ;

Pitts, Sharon ;

Kamranpour, Naeimeh ;

Desai, Amrita J. ;

Hosmer, Wylie ;

Ide, Susan ;

Avsar, Emin ;

Jensen, Michael Rugaard ;

Quadt, Cornelia ;

Liu, Manway ;

Dubinett, Steven M. ;

Slamon, Dennis J. .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) :890-900

[22]

Gettinger SN, 2015, WORLD C LUNG CANC DE

[23] Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors [J].

Goldberg, Sarah B. ;

Oxnard, Geoffrey R. ;

Digumarthy, Subba ;

Muzikansky, Alona ;

Jackman, David M. ;

Lennes, Inga T. ;

Sequist, Lecia V. .

ONCOLOGIST, 2013, 18 (11) :1214-1220

[24] SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA [J].

GREEN, S ;

WEISS, GR .

INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :239-253

[25]

Horn L, 2014, CHIC MULT S THOR ONC

[26] EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset [J].

Inamura, Kentaro ;

Takeuchi, Kengo ;

Togashi, Yuki ;

Hatano, Satoko ;

Ninomiya, Hironori ;

Motoi, Noriko ;

Mun, Ming-yon ;

Sakao, Yukinori ;

Okumura, Sakae ;

Nakagawa, Ken ;

Soda, Manabu ;

Choi, Young Lim ;

Mano, Hiroyuki ;

Ishikawa, Yuichi .

MODERN PATHOLOGY, 2009, 22 (04) :508-515

[27] Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations [J].

Johnson, Ted W. ;

Richardson, Paul F. ;

Bailey, Simon ;

Brooun, Alexei ;

Burke, Benjamin J. ;

Collins, Michael R. ;

Cui, J. Jean ;

Deal, Judith G. ;

Deng, Ya-Li ;

Dinh, Dac ;

Engstrom, Lars D. ;

He, Mingying ;

Hoffman, Jacqui ;

Hoffman, Robert L. ;

Huang, Qinhua ;

Kania, Robert S. ;

Kath, John C. ;

Lam, Hieu ;

Lam, Justine L. ;

Le, Phuong T. ;

Lingardo, Laura ;

Liu, Wei ;

McTigue, Michele ;

Palmer, Cynthia L. ;

Sach, Neal W. ;

Smeal, Tod ;

Smith, Graham L. ;

Stewart, Albert E. ;

Timofeevski, Sergei ;

Zhu, Huichun ;

Zhu, Jinjiang ;

Zou, Helen Y. ;

Edwards, Martin P. .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) :4720-4744

[28] Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers [J].

Katayama, Ryohei ;

Shaw, Alice T. ;

Khan, Tahsin M. ;

Mino-Kenudson, Mari ;

Solomon, Benjamin J. ;

Halmos, Balazs ;

Jessop, Nicholas A. ;

Wain, John C. ;

Yeo, Alan Tien ;

Benes, Cyril ;

Drew, Lisa ;

Saeh, Jamal Carlos ;

Crosby, Katherine ;

Sequist, Lecia V. ;

Iafrate, A. John ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)

[29] Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance [J].

Kodama, Tatsushi ;

Tsukaguchi, Toshiyuki ;

Yoshida, Miyuki ;

Kondoh, Osamu ;

Sakamoto, Hiroshi .

CANCER LETTERS, 2014, 351 (02) :215-221

[30] Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer [J].

Kuriyama, Yuka ;

Kim, Young Hak ;

Nagai, Hiroki ;

Ozasa, Hiroaki ;

Sakamori, Yuichi ;

Mishima, Michiaki .

CASE REPORTS IN ONCOLOGY, 2013, 6 (02) :430-433

← 1 2 3 4 5 6 →